Vantage logo

Is valrox dead?

Valrox leaves a disproportionate hole in Biomarin’s valuation, but gene therapy competitors shouldn’t celebrate just yet.

Vantage logo

Bristol bets on cytokines again

The company’s deal with Dragonfly shows that disappointments have not eliminated interest in cytokine approaches.